Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.

It is generally accepted that human cancers derive from a mutated single cell. However, the genetic steps characterizing various stages of progression remain unclear. Studying a unique case of metastatic melanoma, we observed that cell lines derived from metachronous metastases arising over a decade retained a central core of genetic stability in spite of divergent phenotypes. In the present study, we expanded our previous observations comparing these autologous cell lines of clonal derivation with allogeneic ones and correlated array comparative genomic hybridization (aCGH) with gene expression profiling to determine their relative contribution to the dynamics of disease progression. aCGH and gene expression profiling were performed on autologous cell lines and allogeneic melanoma cell lines originating from other patients. A striking correlation existed between total extent of genetic imbalances, global transcriptional patterns, and cellular phenotypes. They did not follow a strict temporal progression but stemmed independently at various time points from a central core of genetic stability best explained according to the cancer stem cell hypothesis. Although their contribution was intertwined, genomic imbalances detectable by aCGH contributed only 25% of the transcriptional traits determining autologous tumor distinctiveness. Our study provides important insights about the dynamics of cancer progression and supports the development of targeted anticancer therapies aimed against stable genetic factors that are maintained throughout the end stage of disease.

[1]  F. Marincola,et al.  A gene expression signature associated with survival in metastatic melanoma , 2006, Journal of Translational Medicine.

[2]  Aiqing He,et al.  Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids , 2006, Proceedings of the National Academy of Sciences.

[3]  F. Marincola,et al.  Clonal persistence and evolution during a decade of recurrent melanoma. , 2006, The Journal of investigative dermatology.

[4]  J. Grichnik Genomic instability and tumor stem cells. , 2006, The Journal of investigative dermatology.

[5]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[6]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[7]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[8]  U. Urzúa,et al.  Microarray Comparative Genomic Hybridization Profile of a Murine Model for Epithelial Ovarian Cancer Reveals Genomic Imbalances Resembling Human Ovarian Carcinomas , 2005, Tumor Biology.

[9]  E. Wang RNA amplification for successful gene profiling analysis , 2005, Journal of Translational Medicine.

[10]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[11]  D. Pinkel,et al.  Array comparative genomic hybridization and its applications in cancer , 2005, Nature Genetics.

[12]  P. Lieu,et al.  Development of a DNA-labeling system for array-based comparative genomic hybridization. , 2005, Journal of biomolecular techniques : JBT.

[13]  Karl J. Dykema,et al.  Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma , 2005, BMC Genomics.

[14]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[15]  S. Rasheed,et al.  Is Melanoma a stem cell tumor? Identification of neurogenic proteins in trans-differentiated cells , 2005, Journal of Translational Medicine.

[16]  F. Marincola,et al.  HLA class I and II genotype of the NCI-60 cell lines , 2005, Journal of Translational Medicine.

[17]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[18]  W. Stolz,et al.  Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. , 2005, The Journal of investigative dermatology.

[19]  F. Marincola,et al.  Melanoma-restricted genes , 2004, Journal of Translational Medicine.

[20]  S. Adams,et al.  Ambiguous allele combinations in HLA Class I and Class II sequence-based typing: when precise nucleotide sequencing leads to imprecise allele identification , 2004, Journal of Translational Medicine.

[21]  F. Marincola,et al.  Selection and validation of endogenous reference genes using a high throughput approach , 2004, BMC Genomics.

[22]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[23]  S. Spiegl-Kreinecker,et al.  Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes , 2003, Melanoma research.

[24]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[25]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[26]  S K Libutti,et al.  Advantages of mRNA amplification for microarray analysis. , 2002, BioTechniques.

[27]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[29]  Steve Goodison,et al.  Comprehensive karyotyping of the HT‐29 colon adenocarcinoma cell line , 2002, Genes, chromosomes & cancer.

[30]  P. Meltzer,et al.  Application of molecular cytogenetic techniques in a case study of human cutaneous metastatic melanoma. , 2001, Cancer genetics and cytogenetics.

[31]  O. Olopade,et al.  Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. , 2001, Cancer genetics and cytogenetics.

[32]  R. Ádány,et al.  Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. , 2001, Cytometry.

[33]  M. Radmacher,et al.  Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. , 2000, Cancer genetics and cytogenetics.

[34]  M. Peinado,et al.  Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. , 2000, Cancer genetics and cytogenetics.

[35]  F. Marincola,et al.  High-fidelity mRNA amplification for gene profiling , 2000, Nature Biotechnology.

[36]  F. Marincola,et al.  Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells , 1999, The Journal of experimental medicine.

[37]  F. Marincola,et al.  Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model , 1999, International journal of cancer.

[38]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[39]  D. Pinkel,et al.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.

[40]  S. Steinberg,et al.  Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.

[41]  P. Carroll,et al.  Frequent homozygous deletion of cyclin‐dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization , 1997, Genes, chromosomes & cancer.

[42]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[43]  C. Shields,et al.  Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma , 1996, International journal of cancer.

[44]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[45]  D. Sidransky Screening for clonal genetic alterations. , 1995, European journal of cancer.

[46]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[47]  P. Iannaccone,et al.  On the clonal origin of tumors: A review of experimental models , 1987, International journal of cancer.

[48]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[49]  J. A. Burch,et al.  Melanoma, a tumor based on a mutant stem cell? , 2006, The Journal of investigative dermatology.

[50]  A. Schäffer,et al.  Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. , 2002, Neoplasia.

[51]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[52]  E. Schröck,et al.  Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. , 1999, Cancer research.